Literature DB >> 21221869

Papillary thyroid carcinoma variants.

Ricardo V Lloyd1, Darya Buehler, Elham Khanafshar.   

Abstract

Papillary thyroid carcinomas are the most common thyroid cancers and constitute more than 70% of thyroid malignancies. The most common etiologic factor is radiation, but genetic susceptibility and other factors also contribute to the development of papillary thyroid carcinoma. The most common variants include conventional, follicular variant and tall cell variant. However, many other uncommon variants have been described including oncocytic, columnar cell, diffuse sclerosing and solid forms. Immunohistochemical staining with TTF-1 and thyroglobulin is very useful in confirming the diagnosis of papillary thyroid carcinoma especially in metastatic sites. Markers such as HBME-1 and CITED1 can assist in separating some difficult cases of follicular variants of papillary thyroid carcinomas from follicular adenomas. Molecular studies have shown that the BRAF V600E mutation is found mainly in papillary and anaplastic thyroid carcinomas. Other molecular markers such as HMGA2 and insulin-like growth factor II mRNA binding protein 3 have been used recently as molecular tests to separate papillary thyroid carcinoma and its variants from follicular adenomas and other benign thyroid nodules.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21221869      PMCID: PMC3037461          DOI: 10.1007/s12105-010-0236-9

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  18 in total

1.  The many appearances of papillary carcinoma of the thyroid.

Authors:  W A Hawk; J B Hazard
Journal:  Cleve Clin Q       Date:  1976 WINTER

2.  Diffuse sclerosing variant is a major subtype of papillary thyroid carcinoma in the young.

Authors:  Ja Seung Koo; Soonwon Hong; Cheong Soo Park
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

3.  Prognostic implications of the tall cell variant of papillary thyroid carcinoma.

Authors:  T L Johnson; R V Lloyd; N W Thompson; W H Beierwaltes; J C Sisson
Journal:  Am J Surg Pathol       Date:  1988-01       Impact factor: 6.394

4.  Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma.

Authors:  Theresa Scognamiglio; Elizabeth Hyjek; Jean Kao; Yao-Tseng Chen
Journal:  Am J Clin Pathol       Date:  2006-11       Impact factor: 2.493

Review 5.  Carcinomas with micropapillary morphology: clinical significance and current concepts.

Authors:  Hind Nassar
Journal:  Adv Anat Pathol       Date:  2004-11       Impact factor: 3.875

6.  Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases.

Authors:  Sofia Asioli; Lori A Erickson; Thomas J Sebo; Jun Zhang; Long Jin; Geoffrey B Thompson; Ricardo V Lloyd
Journal:  Am J Surg Pathol       Date:  2010-01       Impact factor: 6.394

7.  Histologic variants of papillary and follicular carcinomas associated with anaplastic spindle and giant cell carcinomas of the thyroid: an analysis of rhabdoid and thyroglobulin inclusions.

Authors:  Jorge Albores-Saavedra; Mercedes Hernandez; Sergio Sanchez-Sosa; Karen Simpson; Arturo Angeles; Donald E Henson
Journal:  Am J Surg Pathol       Date:  2007-05       Impact factor: 6.394

8.  The Delphian lymph node in thyroid cancer.

Authors:  Joseph D Isaacs; Catharina I Lundgren; Stan B Sidhu; Mark S Sywak; Pam J Edhouse; Leigh W Delbridge
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

9.  Hürthle cell (oxyphilic) papillary thyroid carcinoma: a variant with more aggressive biologic behavior.

Authors:  M F Herrera; I D Hay; P S Wu; J R Goellner; J J Ryan; J R Ebersold; E J Bergstralh; C S Grant
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

Review 10.  Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis.

Authors:  Marina N Nikiforova; Yuri E Nikiforov
Journal:  Expert Rev Mol Diagn       Date:  2008-01       Impact factor: 5.225

View more
  79 in total

1.  MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells.

Authors:  Hong-Ming Song; Yi Luo; Deng-Feng Li; Chuan-Kui Wei; Kai-Yao Hua; Jia-Lu Song; Hui Xu; Niraj Maskey; Lin Fang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

2.  Follicular variant of papillary thyroid cancer in Alström syndrome.

Authors:  M Papadakis; A Meyer; F Schuster; N Weyerbrock; C Corinth; C Dotzenrath
Journal:  Fam Cancer       Date:  2015-12       Impact factor: 2.375

3.  Relationships of FOXE1 and ATM genetic polymorphisms with papillary thyroid carcinoma risk: a meta-analysis.

Authors:  Jie Kang; Xian-Zhao Deng; You-Ben Fan; Bo Wu
Journal:  Tumour Biol       Date:  2014-04-24

4.  Papillary thyroid cancer nodal metastases mimicking a slow-flow lymphatic malformation.

Authors:  Munira Ally; Neeral Patel; Kunwar Bhatia; Zaid Awad
Journal:  BMJ Case Rep       Date:  2018-07-06

5.  MicroRNA-409-3p suppresses cell proliferation and cell cycle progression by targeting cyclin D2 in papillary thyroid carcinoma.

Authors:  Zhijun Zhao; Fei Yang; Yan Liu; Kai Fu; Shanghua Jing
Journal:  Oncol Lett       Date:  2018-08-01       Impact factor: 2.967

6.  Lymph node metastases do not impact survival in follicular variant papillary thyroid cancer.

Authors:  David F Schneider; Dawn Elfenbein; Ricardo V Lloyd; Herbert Chen; Rebecca S Sippel
Journal:  Ann Surg Oncol       Date:  2014-08-05       Impact factor: 5.344

7.  Identification of a novel HRAS variant and its association with papillary thyroid carcinoma.

Authors:  Rui Dou; Lili Zhang; Tingxia Lu; Dong Liu; Fang Mei; Jian Huang; Linxue Qian
Journal:  Oncol Lett       Date:  2018-01-17       Impact factor: 2.967

8.  Clinicopathological characteristics of thyroid cancer misdiagnosed by fine needle aspiration.

Authors:  Hideki Maeda; Goro Kutomi; Fukino Satomi; Hiroaki Shima; Mitsuru Mori; Koichi Hirata; Ichiro Takemasa
Journal:  Exp Ther Med       Date:  2016-09-01       Impact factor: 2.447

9.  Expression of PACAP and PAC1 Receptor in Normal Human Thyroid Gland and in Thyroid Papillary Carcinoma.

Authors:  Sebastian Bardosi; Attila Bardosi; Zsuzsanna Nagy; Dora Reglodi
Journal:  J Mol Neurosci       Date:  2016-08-26       Impact factor: 3.444

Review 10.  [The role of pathology in the diagnostics of CUP syndrome].

Authors:  A Stenzinger; M Kriegsmann; W Weichert
Journal:  Radiologe       Date:  2014-02       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.